The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.
 
Tony R. Reid
Employment - Epicentrx
Leadership - Epicentrx
Stock and Other Ownership Interests - Epicentrx
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech/Roche
Research Funding - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Epicentrx licensed patented technology
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Genentech; Ipsen; Merck; Novartis
Consulting or Advisory Role - Aduro Biotech; Aduro Biotech; Forty Seven; Genentech/Roche; Incyte; ipsen; Jounce Therapeutics; Merck; Newlink Genetics
Research Funding - Aduro Biotech (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Jounce Therapeutics (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); TERUMO (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme